Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration
Robert P Finger, Marie-Therese Puth, Matthias Schmid, Daniel Barthelmes, Robyn H Guymer, Mark Gillies
JAMA Ophthalmology | AMER MEDICAL ASSOC | Published : 2020
Importance: Neovascular age-related macular degeneration (nAMD), the largest single cause of irreversible severe vision loss in high-income countries, can now be treated with vascular endothelial growth factor (VEGF) inhibitors, but to our knowledge, no data on lifetime outcomes are available. Objective: To determine visual acuity (VA) outcomes of anti-VEGF treatment for nAMD in both eyes for patients' remaining lifetime. Design, Setting, and Participants: Multistate modeling using real-world cohort data of 3192 patients with nAMD (>67 000 visits) treated in routine eye clinics in Australia, New Zealand, and Switzerland. Data were analyzed between 2007 and 2015. Exposures: Intravitreal anti-..View full abstract
Awarded by German Scholars Organization/Else Kroner Fresenius Stiftung
Awarded by National Health and Medical Research Council of Australia
This work was in part supported by the German Scholars Organization/Else Kroner Fresenius Stiftung (GSO/EKFS-16). The Fight Retinal Blindness Project was supported by a grant from the Royal Australian and New Zealand College of Ophthalmologists Eye Foundation (2007-2009); a grant from the National Health and Medical Research Council, Australia (NHMRC 2010-2012); and a grant from the Macular Disease Foundation, Australia. Dr Gillies is a Sydney Medical Foundation Fellow and is supported by an National Health and Medical Research Council, Australia practitioner fellowship. Dr Barthelmes was supported byWalter Gertrud Siegenthaler Foundation, Zurich, Switzerland, and the Swiss National Foundation. Dr Guymer was supported by National Health and Medical Research Council of Australia fellowship grant GNT1103013. Centre for Eye Research receives operational infrastructure support from the Victorian government.